This week's roundup of Houston innovators includes Peter Rodriguez of Rice University, Kike Oduba of WellnessWits, and Phil Sitter of RepeatMD. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries recently making headlines in Houston across business, software, and digital health.

Peter Rodriguez, dean of Rice University's Jones Graduate School of Business

Peter Rodriguez joins the Houston Innovators Podcast to discuss the school's growth and development as an innovation leader. Photo courtesy Annie Tao/Rice University

Entrepreneurship doesn't require a MBA from Rice University, but Dean Peter Rodriguez wants to make sure that the students who do pass through the halls of the Jesse H. Jones Graduate School of Business are well prepared for creating a successful company.

"We really want to be the deliverer of the software in people's brain of how to launch great companies and to be trumpeting the opportunities here," he says on the Houston Innovators Podcast.

Rodriguez joined the school as dean in 2016, and since then he's doubled MBA enrollment, grown the tenure-track faculty by over 40 percent, launched an online graduate degree, created an undergraduate business major, and more.

"When I came here, I thought Rice had the best strategic foundation of any university for a great business school — and a lot of that is being really closely connected to Houston and bringing in innovation," he says on the show. Read more.

Kike Oduba, founder and CEO of WellnessWits

WellnessWits, founded by Kike Oduba to enhance patient-physician interaction, has integrated AI with the help of IBM. Photo via WellnessWits.com

A Houston startup aimed at transforming healthcare with solutions for chronic disease and its prevention has teamed up with IBM technology.

WellnessWits has embedded IBM watsonx Assistant into its app for both iOS and Android. By making generative AI part of the app, WellnessWits now boasts an AI-based chat functionality.

That cutting-edge aspect of the platform allows patients to get information on chronic disease more quickly than ever, even before meeting with their physician. But it helps with that, too, aiding in scheduling appointments more easily with doctors who specialize in a host of chronic maladies.

“I founded WellnessWits as a platform for shared medical appointments where doctors with large patient loads can see them in groups and offer collective shared medical experiences to people suffering from chronic conditions. The goal is to bridge this divide, leveraging the strength of digital communities to enhance the overall well-being and healthcare experiences of individuals everywhere,” WellnessWits Founder and CEO Dr. Kike Oduba, a physician and informatician, writes in a blog post. Read more.

Phil Sitter, founder and CEO of RepeatMD

Fresh off a win at the Houston Innovation Awards, Phil Sitter's RepeatMD has raised funding. Photo via RepeatMD

Just nine months after its seed round, a Houston startup with a software platform for the aesthetic and wellness industry has secured $40 million in venture capital and $10 million in debt facility.

RepeatMD, a SaaS platform, announced today that it's secured $50 million, which includes a $10 million debt facility from Silicon Valley Bank. The round was co-led by Centana Growth Partners and Full In Partners with participation from PROOF and Mercury Fund, which also contributed to the seed round earlier this year.

The mobile ecommerce platform, launched in October 2021 by Phil Sitter, targets practices within the med spa and aesthetics industry. In the United States, the med spa market is slated to hit $19 billion in 2023, according to the company's press release, while the global aesthetics market is forecasted to reach to nearly $332 billion by 2030.

“Even though the aesthetics and wellness industry has continued to innovate a growing range of life-changing treatments, practices continue to face challenges selling treatments and services that are new and unfamiliar to patients,” Sitter, CEO of RepeatMD, says in the release. “Our goal at RepeatMD is to give these practice owners the technology to elevate their patients’ experience. Our platform serves as a med-commerce engine equipped with the same firepower as large retailers to convert sales inside and outside of practice operating hours.” Read more.

WellnessWits, founded by Kike Oduba to enhance patient-physician interaction, has integrated AI with the help of IBM. Photo via WellnessWits.com

Houston health tech startup taps into IBM tech for AI integration

teaming up

A Houston startup aimed at transforming healthcare with solutions for chronic disease and its prevention has teamed up with IBM technology.

WellnessWits has embedded IBM watsonx Assistant into its app for both iOS and Android. By making generative AI part of the app, WellnessWits now boasts an AI-based chat functionality.

That cutting-edge aspect of the platform allows patients to get information on chronic disease more quickly than ever, even before meeting with their physician. But it helps with that, too, aiding in scheduling appointments more easily with doctors who specialize in a host of chronic maladies.

“I founded WellnessWits as a platform for shared medical appointments where doctors with large patient loads can see them in groups and offer collective shared medical experiences to people suffering from chronic conditions. The goal is to bridge this divide, leveraging the strength of digital communities to enhance the overall well-being and healthcare experiences of individuals everywhere,” WellnessWits Founder and CEO Dr. Kike Oduba, a physician and informatician, writes in a blog post.

Oduba founded the company in 2018. In its early years, she participated in IBM’s First AI Cohort for Underrrepresented Founders Program. She believes that by using watsonx Assistant in her technology arsenal, WellnessWits will be a means to “digitize, standardize and automate care plans for patients dealing with chronic diseases.”

Diabetes management is a cornerstone of the company, but Oduba says that WellnessWits is similarly committed to impacting health issues including cancer, chronic pain, mental health, and obesity.

“By partnering with IBM, and academic leaders in institutions like The University of Texas, we aim to extend our reach and impact,” Oduba says.

In addition to the IBM program, Oduba and WellnessWits was selected for MassChallenge's recent cohort.

MassChallenge Startup Stories: WellnessWits Founder's Journey from Struggles to SuccessIn this inspiring 6-minute testimonial, we take you through the remarkable experience of Dr. Oduba, founder and CEO of ...

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.